NEW
Stock Screener with Intrinsic Value
Gilead Sciences, Inc. (GILD)
Last Price$91.80.2%
Market Cap$114.5B
WACC
6.7%
Cost of Equity
7.8%
Cost of Debt
1.3%
Debt to Equity
20.3%
Beta
0.8
Stock quality
7/10
Good
GILD WACC
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
GILD Cost of Equity
Crunching data... Almost there!
GILD vs Peer Set: Discount Rate Comparison
WACC
Cost of Equity
General
Discount rate
financials
Company name
Revenue growth
EPS growth
Net Income margin
Gilead Sciences, Inc.GILD
6.7%
(0.6%)
24.0%
20.9%
Median Peer Set
6.5%
1.4%
(15.9%)
15.4%
Eli Lilly and CompanyLLY
7.5%
19.6%
(15.9%)
15.4%
Johnson & JohnsonJNJ
7.2%
6.5%
102.3%
41.3%
Merck & Co., Inc.MRK
6.9%
1.4%
(97.6%)
0.6%
Novartis AGNVS
6.8%
(10.0%)
124.1%
31.8%
AbbVie Inc.ABBV
6.5%
(6.4%)
(58.9%)
9.0%
Amgen Inc.AMGN
5.9%
7.1%
3.1%
23.8%
Pfizer Inc.PFE
5.8%
(41.7%)
(93.2%)
3.6%
Bristol-Myers Squibb CompanyBMY
5.6%
(2.5%)
30.6%
17.8%
SanofiSNY
negative
4.1%
(33.9%)
11.7%
Explore more intrinsic value tools hub for GILD
Peter Lynch Fair Value
Margin of safety
Reverse DCF
Relative Value
DCF value calculator
Ben Graham Fair Value
Intrinsic Value
Peter Lynch charts
Earnings growth model
Earnings Power Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Gilead Sciences, Inc.'s discount rate as of Jan 17, 2025?
As of Jan 17, 2025, Gilead Sciences, Inc.'s discount rate is 6.73%. This rate is determined based on the weighted average cost of capital (WACC) and the cost of equity, factoring in Gilead Sciences, Inc.'s capital structure and risk profile.
What is Gilead Sciences, Inc.'s weighted average cost of capital (WACC)?
Gilead Sciences, Inc.'s WACC as of Jan 17, 2025, is 6.73%. This value is calculated by blending the cost of debt and cost of equity, reflecting the company’s overall cost of financing its operations.
What is Gilead Sciences, Inc.'s cost of equity?
Gilead Sciences, Inc.'s cost of equity is 7.8%, as of Jan 17, 2025. This is the return that shareholders expect based on the stock's risk level and market conditions, used to calculate the discount rate for valuing future cash flows.